Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Kiniksa Pharmaceuticals International (KNSA) Income from Continuing Operations (2021 - 2025)

Kiniksa Pharmaceuticals International (KNSA) has disclosed Income from Continuing Operations for 5 consecutive years, with 24426000.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Income from Continuing Operations rose 3330.95% year-over-year to 24426000.0, compared with a TTM value of 69232000.0 through Dec 2025, up 297.46%, and an annual FY2025 reading of 69232000.0, up 297.46% over the prior year.
  • Income from Continuing Operations was 24426000.0 for Q4 2025 at Kiniksa Pharmaceuticals International, up from 18435000.0 in the prior quarter.
  • Across five years, Income from Continuing Operations topped out at 224093000.0 in Q3 2022 and bottomed at 49484000.0 in Q1 2021.
  • Average Income from Continuing Operations over 5 years is 6164700.0, with a median of 8089000.0 recorded in 2023.
  • The sharpest move saw Income from Continuing Operations tumbled 126.1% in 2024, then soared 3330.95% in 2025.
  • Year by year, Income from Continuing Operations stood at 44078000.0 in 2021, then skyrocketed by 110.12% to 4461000.0 in 2022, then surged by 1751.2% to 82582000.0 in 2023, then tumbled by 100.92% to 756000.0 in 2024, then skyrocketed by 3330.95% to 24426000.0 in 2025.
  • Business Quant data shows Income from Continuing Operations for KNSA at 24426000.0 in Q4 2025, 18435000.0 in Q3 2025, and 17832000.0 in Q2 2025.